CMS announced it would begin an official process to determine whether a national policy is necessary for Aduhelm and other drugs in development like it, responding to calls from insurers and patient advocates.
Original source: https://www.healthcaredive.com/news/medicare-alzheimers-aduhelm-coverage-policy-biogen/603217/